Učitavanje...
Programmed death‐ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer
Immune checkpoint inhibitor therapy has been clinically introduced for several malignancies, and its effectiveness has been confirmed by clinical trials. In particular, programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) are widely known as important immune checkpoint molecu...
Spremljeno u:
| Izdano u: | Cancer Sci |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5834808/ https://ncbi.nlm.nih.gov/pubmed/29345842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13508 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|